Oregon is currently home to 1244 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Portland, Eugene, Medford and Clackamas. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Navigation and Parent Peer Support to Promote Access
NCT04029220
Recruiting
Nearly one in five children in the United States has a mental health problem that interferes with daily functioning and requires intervention, and yet less than 50% of children who need mental health care receive any services. Families and especially from low-income and ethnically diverse backgrounds, experience a range of barriers to engaging in services for their children including: lack of recognition of problems and knowledge of available treatments, connecting to services, trust in provider... Read More
Gender:
All
Ages:
Between 1 year and 99 years
Trial Updated:
08/15/2022
Locations: Oregon Family Support Network, Salem, Oregon
Conditions: Mental Disorder, Child, Mental Health, Family Health
Register for Updates
Comparative Effectiveness of Cryoablation Versus Steroid and Lidocaine Alone for Treatment of Morton's Neuroma
NCT05501262
Recruiting
Morton's neuroma is a benign thickening involving the plantar interdigital nerve, most common in middle aged women. Morton's neuroma is one of the most frequent diagnoses seen in the investigators podiatry clinic and is difficult to treat. These lesions cause a burning or shooting pain that can radiate to the toes, or an aching pain in the ball of the foot. The pain is exacerbated with activity and certain footwear greatly limits activity in the involved patient population. Morton's neuroma is f... Read More
Gender:
All
Ages:
Between 18 years and 105 years
Trial Updated:
08/11/2022
Locations: Oregon Health Sciences University, Portland, Oregon
Conditions: Morton Neuroma
Register for Updates
Sleep Duration and Cardiovascular Health
NCT04804124
Recruiting
This is a cross-sectional study with an optional intervention that will examine how extreme sleep durations relate to cardiovascular health, physical activity, and sleep quality by studying three groups of participants: short sleepers (≤ 6 hrs), long sleepers (≥ 9 hrs), and average duration sleepers (7-8 hrs). The optional intervention asks participants to maintain an 8-hour per night regular sleep schedule for one week.
Gender:
All
Ages:
Between 25 years and 65 years
Trial Updated:
08/10/2022
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Sleep, Cardiovascular Risk Factor
Register for Updates
Sedentary Behavior, Cardiovascular Function, and Sleep
NCT04137068
Recruiting
This is an interventional study that will examine how sedentary behavior (decreased physical inactivity) over time affects cardiovascular health (i.e. heart rate and blood pressure) and sleep quality/duration.
Gender:
All
Ages:
Between 20 years and 80 years
Trial Updated:
08/03/2022
Locations: Oregon Institute of Occupational Health Sciences, Portland, Oregon
Conditions: Sedentary Behavior, Cardiovascular Function, Sleep
Register for Updates
Effect of Daily Consumption of Glycomacropeptide on Gut Microbiome and Blood Functional Proteome of Subjects With Irritable Bowel Syndrome
NCT05482464
Recruiting
This study investigates the use of glycomacropeptide (GMP) as a means to manipulate the gut microbiome, metabolome and protein profile of subjects with irritable bowel syndrome (IBS).
Gender:
All
Ages:
Between 18 years and 30 years
Trial Updated:
07/28/2022
Locations: Milam Hall, Room 001, Corvallis, Oregon
Conditions: Inflammatory Bowel Syndrome
Register for Updates
Correlation Between Intraoperative Tourniquet Use and Limb pH, Functional Measures and Patient-reported Outcomes After Ankle Fracture Surgery
NCT05445960
Recruiting
This study aims to 1) characterize skeletal muscle pH during/after tourniquet use and 2) investigate any relationship between intraoperative tourniquet use and postoperative functional measures and patient-reported outcomes.
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
06/30/2022
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Ankle Fractures, Ankle Fracture - Lateral Malleolus, Ankle Fracture, Bimalleolar, Ankle Fracture, Trimalleolar, Ankle Fracture - Medial Malleolus, Maisonneuve's Fracture, Syndesmotic Injuries, Fibula Fracture
Register for Updates
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
NCT03394365
Recruiting
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab and rituximab plus chemotherapy or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
Gender:
All
Ages:
All
Trial Updated:
06/23/2022
Locations: Oregon Health and Science University Physicians Pavilion (Adults and Pediatrics), Portland, Oregon
Conditions: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
Register for Updates
Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
NCT04116775
Recruiting
All patients will be required to have a biopsy of a metastatic tumor deposit at study entry. Pembrolizumab will be administered at a dose of 200 mg as a 30 minute IV infusion every 3 weeks. Enzalutamide will be continued at dose of 160 mg orally every day. Patients who have neither rapid disease progression or disease response will undergo a fecal microbiota transplant, have a second biopsy (if medically feasible), and be re-treated with pembrolizumab.
Gender:
Male
Ages:
18 years and above
Trial Updated:
06/21/2022
Locations: VA Portland Health Care System, Portland, Oregon
Conditions: Prostate Cancer, Prostate Cancer Metastatic
Register for Updates
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
NCT02498951
Recruiting
This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response) or a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment (partial response). Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to gro... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/09/2022
Locations: Providence Portland Medical Center, Portland, Oregon
Conditions: Central Nervous System B-Cell Non-Hodgkin Lymphoma
Register for Updates
Immunological Effect of Increasing Doses of Natural Peptide
NCT05176678
Recruiting
A trial monitoring the immune effects in 24 people with 4 different doses (1 gram per day, 2 grams per day, 4 grams per day, 8 grams per day) of a natural plant-based protein hydrolysate.
Gender:
All
Ages:
Between 25 years and 65 years
Trial Updated:
06/07/2022
Locations: Gitte Jensen, Klamath Falls, Oregon
Conditions: Pharmacokinetics
Register for Updates
Clinical Study on Rapid Antioxidant Protection and Immune Modulating Effects.
NCT05042674
Recruiting
A trial on acute antioxidant protection and immune effects when 24 people consume a novel nutraceutical blend compared to a placebo on different test days.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/07/2022
Locations: NIS Labs, Klamath Falls, Oregon
Conditions: Pharmacokinetics
Register for Updates
Clinical Proof-of-concept Study on Rapid Immune Modulating Effects
NCT05364710
Recruiting
Clinical-proof-of concept study, comparing the acute immune impacts of of 2 doses of a novel blend of supplements to a placebo. This study involves twenty-four participants, composed of healthy adults, who will be taking a placebo and 2 different doses of the blend at different times. Testing for immune status and cytokine levels will be conducted to determine the acute impact of the blend on immune function as compared to the placebo.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/11/2022
Locations: NIS Labs, Klamath Falls, Oregon
Conditions: Immune Surveillance
Register for Updates